Receptor Tyrosine Kinases and Inhibitors in Lung Cancer by Evan Pisick, Simha Jagadeesh, Ravi Salgia

“…Knowing cellular pathways helps to further enhance our knowledge of how lung cancer cells survive, proliferate, and metastasize. The receptor tyrosine kinases (RTKs) located at the cellular membrane are becoming of great interest as sites for targeted therapies for lung cancers. …”
Get full text

USP8‐Dependent Family Tyrosine Kinase Promotes the Malignant Progression of Esophageal Squamous Cell Carcinoma by Upregulating Protein Tyrosine Kinase 2 Expression by Yuechang Wu, Dubiao Xian, Yunzhong Liu, Ding Huang, Qingfeng Liu, Shubo Yang

“…FYN proto‐oncogene, Src family tyrosine kinase (FYN) has been linked to cancer progression, yet its role in ESCC remains elusive. …”
Get full text

Role of Bruton's Tyrosine Kinase in B Cell Development by Alex Maas, Rudolf W. Hendriks

Get full text

Baicalin and Baicalein Inhibit Src Tyrosine Kinase and Production of IL-6 by Dubravko Jelić, Agnieszka D. Lower-Nedza, Adelheid H. Brantner, Biljana Blažeković, Baolin Bian, Jian Yang, Karmen Brajša, Sanda Vladimir-Knežević

“…Thereby the two compounds were investigated on Src tyrosine kinase inhibition and inhibition of production of interleukin (IL-6) in lipopolysaccharide- (LPS-) stimulated THP-1 cells. …”
Get full text

Muscle-Specific Tyrosine Kinase-Associated Myasthenia Gravis: A Neuromuscular Surprise by Hassam Ali, Rahul Pamarthy, Nayab Ahsan, null WashmaAwan, Shiza Sarfraz

“…Although most commonly caused by antibodies to the acetylcholine receptor, antibodies against MuSK (muscle-specific kinase) protein can also weaken transmission at the neuromuscular junction. Muscle-specific tyrosine kinase myasthenia gravis (MuSK-Ab MG) is a rare subtype of myasthenia gravis with distinct pathogenesis and unique clinical features. …”
Get full text

In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli by Jihene Elloumi-Mseddi, Karim Jellali, Sami Aifa

“…The present work concerns the heterologous expression of the intracellular domain harbouring the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). …”
Get full text

Spleen tyrosine kinase inhibitors disrupt human neutrophil swarming and antifungal functions by Alex Hopke, Adam L. Viens, Natalie J. Alexander, Seok Joon Mun, Michael K. Mansour, Daniel Irimia

“…Here, we report that spleen tyrosine kinase (SYK) inhibitors severely impair neutrophil swarming responses, resulting in the complete loss of fungal restriction. …”
Get full text

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors by Nathaniel J. Myall, MD, Jennifer G. Whisenant, PhD, Joel W. Neal, MD, PhD, Wade T. Iams, MD, Karen L. Reckamp, MD, Sally York, MD, PhD, Lynne D. Berry, PhD, Yu Shyr, PhD, Leora Horn, MD, Heather A. Wakelee, MD, Sukhmani K. Padda, MD

“…Introduction: Although tyrosine kinase inhibitors (TKIs) are effective against NSCLC harboring sensitizing EGFR gene mutations, acquired resistance is inevitable. …”
Get full text

Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa by Rochelle Woudberg, Edina Sinanovic

Subjects: Get full text

Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases by Nozomi Sasaki, Yukiko Enomoto, Takamitsu Hori, Hirofumi Matsubara, Yusuke Egashira, Tsuyoshi Izumo

Subjects: Get full text

Pengaruh Likopen terhadap Kadar Soluble FMS-Like Tyrosine Kinase 1 pada Preeklamsi by Vaulinne Basyir, Prima Nanda Fauziah, Akhmad Yogi Pramatirta, Yanwirasti Yanwirasti, Johanes C. Mose, Fadil Oenzil

Get full text

The Expression and Clinical Significance of Different Forms of Mer Receptor Tyrosine Kinase in Systemic Lupus Erythematosus by Huaqun Zhu, Xiaolin Sun, Lei Zhu, Fanlei Hu, Lianjie Shi, Zhanguo Li, Yin Su

Get full text

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia by Benjamin M. Heyman, Stephen S. Opat, Björn E. Wahlin, Meletios-Athanasios C. Dimopoulos, Jorge J. Castillo, Alessandra Tedeschi, Constantine S. Tam, Christian Buske, Roger G. Owen, Véronique Leblond, Judith Trotman, Gisoo Barnes, Wai Y. Chan, Jingjing Schneider, Heather Allewelt, Aileen Cohen, Jeffrey V. Matous

“…Although further investigation is required, this analysis supports the potential use and further exploration of Bruton tyrosine kinase inhibitors to treat PN symptoms in patients with WM. …”
Get full text

Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [Tc] (AH-113018) or CY 5** (AH-112543) Labeled Peptide by Elaine M. Jagoda, Sibaprasad Bhattacharyya, Joseph Kalen, Lisa Riffle, Avrum Leeder, Stephanie Histed, Mark Williams, Karen J. Wong, Biying Xu, Lawrence P. Szajek, Osama Elbuluk, Fabiola Cecchi, Kristen Raffensperger, Meghana Golla, Donald P. Bottaro, Peter Choyke

“…Developing an imaging agent targeting the hepatocyte growth factor receptor protein (Met) status of cancerous lesions would aid in the diagnosis and monitoring of Met-targeted tyrosine kinase inhibitors (TKIS). A peptide targeting Met labeled with [ 99m Tc] had high affinity in vitro (K d = 3.3 nM) and detected relative changes in Met in human cancer cell lines. …”
Get full text

Retraction: Bruton’s tyrosine kinase inhibition attenuates the cardiac dysfunction caused by cecal ligation and puncture in mice by Frontiers Editorial Office

Get full text

The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver by Indra Radek, Jelínková Sandra, Kollárová Katarína, Zahumenská Petra, Dvořák Josef, Dušková Šárka, Dračínská Helena

Subjects: Get full text

A review on the potential of Bruton’s tyrosine kinase (Btk) inhibitor – Ibrutinib for treatment of Multiple Myeloma (MM) by Sze-Ting Bong, Lydia Ngiik-Shiew Law, Jodi Woan-Fei Law

“…Nonetheless, research on novel therapies for effective treatment of MM is ongoing and in this case the involvement of Bruton’s tyrosine kinase (Btk) in B-cell malignancies has made it one of the new therapeutic targets. …”
Get full text

Utility of Bruton’s Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia) by Maroun Bou Zerdan, Jason Valent, Maria Julia Diacovo, Karl Theil, Chakra P. Chaulagain

“…Ibrutinib, acalabrutinib, and zanubrutinib are Bruton tyrosine kinase (BTK) inhibitors approved for certain indolent B cell non-Hodgkin’s lymphoma (NHL). …”
Get full text

Protein tyrosine kinase but not protein kinase C inhibition blocks receptor induced alveolar macrophage activation by K. Pollock, M. T. Withnall

“…The selective enzyme inhibitors genistein and Ro 31-8220 were used to assess the importance of protein tyrosine kinase (PTK) and protein kinase C (PKC), respectively, in N-formyl-methionyl-leucyl-phenylalanine (FMLP) induced generation of superoxide anion and thromboxane B2 (TXB2) in guinea-pig alveolar macrophages (AM). …”
Get full text

Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks by Mingming Tan, Chenwei Pu, Zhenzhen Wang, Chengwei Jin

Subjects: Get full text